126 related articles for article (PubMed ID: 38530204)
21. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
[No Abstract] [Full Text] [Related]
22. Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis.
Bode SFN; Rapp H; Lienert N; Appel H; Fabricius D
Eur Arch Otorhinolaryngol; 2023 Jul; 280(7):3271-3277. PubMed ID: 36738326
[TBL] [Abstract][Full Text] [Related]
23. Real world outcomes of CFTR modulator therapy in Australian adults and children.
Kuek S; McCullagh A; Paul E; Armstrong D
Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one
Daines CL; Tullis E; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Rowe SM; Selvadurai H; Taylor-Cousar JL; Withers NJ; Ahluwalia N; Moskowitz SM; Prieto-Centurion V; Tan YV; Tian S; Weinstock T; Xuan F; Zhang Y; Ramsey B; Griese M;
Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 37945033
[TBL] [Abstract][Full Text] [Related]
25. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash.
Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F
Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296
[TBL] [Abstract][Full Text] [Related]
26. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
[No Abstract] [Full Text] [Related]
27. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
[TBL] [Abstract][Full Text] [Related]
28. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
[TBL] [Abstract][Full Text] [Related]
29. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.
Pallenberg ST; Pust MM; Rosenboom I; Hansen G; Wiehlmann L; Dittrich AM; Tümmler B
Microbiol Spectr; 2022 Oct; 10(5):e0145422. PubMed ID: 36154176
[TBL] [Abstract][Full Text] [Related]
30. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
[TBL] [Abstract][Full Text] [Related]
31. Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.
Fainardi V; Skenderaj K; Ciuni A; Milanese G; Deolmi M; Longo F; Spaggiari C; Sverzellati N; Esposito S; Pisi G
Respir Med; 2023 Sep; 216():107328. PubMed ID: 37321310
[TBL] [Abstract][Full Text] [Related]
32. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
33. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
[TBL] [Abstract][Full Text] [Related]
34. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.
Ryan KJ; Guimbellot JS; Dowell AE; Reed-Walker KD; Kerstner-Wood CD; Anderson JD; Liu Z; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123518. PubMed ID: 36371965
[TBL] [Abstract][Full Text] [Related]
35. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
[TBL] [Abstract][Full Text] [Related]
36. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
J Cyst Fibros; 2024 Feb; ():. PubMed ID: 38388235
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method.
Pigliasco F; Cafaro A; Stella M; Baiardi G; Barco S; Pedemonte N; D'Orsi C; Cresta F; Casciaro R; Castellani C; Calevo MG; Mattioli F; Cangemi G
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831163
[TBL] [Abstract][Full Text] [Related]
38. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
[TBL] [Abstract][Full Text] [Related]
39. Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together.
Kinuani R; Ezri J; Kernen Y; Rochat I; Blanchon S
Front Pediatr; 2024; 12():1378744. PubMed ID: 38655277
[TBL] [Abstract][Full Text] [Related]
40. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]